Status:
COMPLETED
Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus
Lead Sponsor:
Nantou Christian Hospital
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
21-80 years
Phase:
PHASE4
Brief Summary
Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder in which a substantial number of patients cannot attain treatment target despite antidiabetic drugs. The renin-angiotensin system (R...
Eligibility Criteria
Inclusion
- adults over 21 years of age
- clinically diagnosed type 2 diabetes mellitus
- recipients of metformin monotherapy
- compliance with prescriptions and dietary intervention
Exclusion
- recipients of any second-line antidiabetic drug in addition to metformin
- recipients of any antihypertensive medication before study enrollment
- hemoglobin disorders
- chronic kidney disease
- thyroid dysfunction
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 29 2019
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT04707508
Start Date
December 1 2017
End Date
November 29 2019
Last Update
January 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nantou Christian Hospital
Nantou City, Nantou County, Taiwan, 540001